Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417209 · ClinicalTrials.gov registry record · Phase 3
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT00417209: Completed Phase 3 study, sponsored by Sanofi.
NCT00417209 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 408 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00417209, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.
Interventions
- DRUG Capecitabine
- DRUG 5-Fluorouracil
- DRUG Larotaxel (XRP9881)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00417209 record still lists
NCT00417209 is an interventional study that assigns participants to a tested intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00417209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00417209 about?
NCT00417209 is a clinical study titled "Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen". The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously tre...
What is the current status of trial NCT00417209?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2006-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00417209?
The interventions under investigation include: Capecitabine (DRUG), 5-Fluorouracil (DRUG), Larotaxel (XRP9881) (DRUG).
Who is sponsoring clinical trial NCT00417209?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00417209's enrollment target sits among peer trials
408 911th of 2000 higher than 1,088 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia